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Enzyme Defects in the Porphyrias and their Relevance to the 
Biochemical Abnormalities in these Disorders 
JOSEPH R. BLOOMER, M.D. 
Department of Medicine, University of Minnesota, Minneapolis, Minnesota 
Defects in enzymes of the heme biosynthesis pathway 
underlie the biochemical abnormalities which occur in 
the porphyrias. Porphyrins and porphyrin precursors 
are accumulated and excreted in excessive amounts be-
cause of the enzyme defects. This is illustrated by studies 
in protoporphyria and variegate porphyria, disorders in 
which the biochemical abnormalities indicate a defect(s) 
in the terminal part of the heme biosynthesis pathway. 
The activity of h~me synthease (ferrochelatase), which 
catalyzes the chelation of ferrous iron to protoporphyrin, 
is deficient in tissues of patients with protoporphyria. 
This causes protoporphyrin to be accumulated and ex-
creted excessively. In variegate porphyria protopor-
phyrinogen oxidase, which catalyzes the oxidation of 
protoporphyrinogen to protoporphyrin, appears to be 
defective. As a result, protoporphyrinogen may be ex-
creted in increased amounts in bile, where it is subse-
quently auto-oxidized to protoporphyrin. The following 
questions have arisen as a result of the demonstrations 
of enzyme defects in tissues of patients with porphyria: 
(1) Will different defects in the same enzyme be found 
among patients who fulfill the clinical and biochemical 
criteria for diagnosis of a specific porphyria? That is, 
does genetic heterogeneity exist in each of the porphy-
rias? (2) Why do some patients with an enzyme defect 
not h ave biochemical abnormalities? (3) Why is one type 
of tissue, usually the liver, the major site of expression 
of the biochemical abnormality, when the enzyme defect 
can be demonstrated in all tissues? 
The porphyrias are a group of disorders in man in which 
inborn errors of heme biosynthesis cause excessive accumula-
tion and excretion of porphyrins and porphyrin precursors (Fig 
1) . Studies over the past decade have shown that the biochem-
ical abnormalities reflect enzyme defects in the heme biosyn-
thesis pathway. For example, the livers of patients with acute 
intermittent porphyria have deficient activity of uroporphyri-
nogen I synthase [1], which catalyzes the conversion of por-
phobilinogen to uroporphyrinogen. As a result, o-amino-levu-
linic acid and porphobilinogen are excreted in increased 
amounts in the urine. The enzyme is not defective in the livers 
of patients with variegate porphyria and porphyria cutanea 
tarda [1], which have patterns of abnormal porphyrin excretion 
different from that in acute intermittent porphyria. The defect 
in uroporphyrinogen I synthase has also been demonstrated in 
cultured skin fibroblasts and red cell hemolysates from patients 
with acute intermittent porphyria [2-6], reflecting the genetic 
, nature of the disease. 
Enzyme defects have been defined in the other porphyrias as 
~ell [7-28]. The current s tate of information is summarized in 
Table I. My laboratory has investigated protoporphyria and 
variegate porphyria (Table II), disorders in which the increase 
in fecal protoporphyrin indicates there is a defect(s) in the 
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terminal portion of the heme biosynthesis pathway. These 
studies illustrate some of the methods which have been used to 
investigate enzyme defects in the prophyrias and point out the 
questions which have been raised about their biochemical 
expression. 
MATERIALS AND METHODS 
Patient Material 
Each of the patients with protoporphyria or variegate prophyria whO 
participated in the studies had the typical clinical, biochemical , and 
genetic features of the disorder (Table II). All specimens were obtained 
from the patients after informed consent. 
Liver tissue for measurement of heme synthase activity was obtained 
from 7 patients with protoporphyria who were undergoing evaluation 
for hepatobiliary disease. The features of hepatobiliary disease 111 
proto porphyria are discussed in detail elsewhere [29,30)' Ths tissue ~a~ 
obtained by percutaneous needle biopsy in 6 patients, and by surg1ca 
biopsy at minilaparotomy in 1 patient. Histological evaluation of ~ 
portion of the biopsy specimen showed normal features in 2, mild porta
d inflammation in 2, and cirrhosis in 3. Liver tissue was also obtalne 
from 10 control subject. Nine individuals had percutaneous needle 
biopsies for evalua tion of a bnormalities in liver fun ction tests, for 
investigation of fever of unknown origin and granulomatous disease, or 
because they were being considered for metho trexate therapy of pso-
riasis. One brain-dead subj ect who became a kidney donor had tissue 
obtained immediate ly a fter death. The control specimens were either 
normal histologically or had minimal abnormalit ies. The assay of herne 
synthase activity was done on freshly obtained t issue in 8 cases, and 011 
tissue which had been frozen at - 70 °C in 9 cases. The activity in freshlY 
obtained t issue was not discernibly different from that in frozen t issue, 
either for the pat ients or controls. 
Punch biopsies of skin (4 mm) were obtained from 8 patients with 
protoporphyria, 5 patients with variegate prophyria, and 8 age_matched 
normal individu als in order to establish lines of cultured fibrob lastsi 
Fibroblast cultures were also initiated from skin biopsies of 3 sets 0 
par ents of childJ'en with protoporphyria. 
Fibroblast Culture 
Fibroblasts from the patients and normal individuals were cul tured 
in paralle l. In order to obtain a sufficient number of cells for enzyrne 
assay, lines in the 5th to 20th passage were grown to confluence in 690-
cm" roller bottles (Belleo Glass, Vineland, NY) wi th Eagle's minimunl 
essential medium supplemented with 1% nonessential amino ac ids, 100/[ 
fetal calf serum (Flow Laboratories, Rockville, MD) and 100 /lg 0 
kanamycin per millili ter . The confluent cells were rinsed with calciunl-
free, magnesium·free phosphate-buffered saline (pH 7.4), harvested 
wi th 0.25% trypsin (Grand Island Biological, Grand Island, NY) into 
phosph ate-buffered saline, centrifuged fOl' 10 min at 1400 xg, and 
washed. For measurement of heme synthase activ ity, the cells wer~ 
resuspended in 0.25 M sucrose containing 0.05 M Tris HCI (pH 7.5) an 
sonicated 3 t imes at 100 W-sec for 20 sec. For measW'ement of pro to-
porphyrinogen oxidase activity, the cells were resuspended in 0.02 ~~ 
Tris .H e l (pH 8.7) containing 20 mg of Tween-20 per mi llili ter an 
sonicated in the same manner. 
M easurement of Heme Synthase Activity 
Heme synthase activity was measured using a radiochemical assaY 
[7,12]. When the assay was done on sonicated fibroblasts, the reactioIl 
mixture conta ined 1 to 3 mg of ce ll protein, 1 to 2 /lCi of rad ioactive 
iron (New England Nuclear, Boston, MA), 25 /lM ferrous sulfate, 25 iJM 
protoporphyrin, 3.5 mM ascorbic acid , 40 mg of Tween-20, and 233 rnM 
Tris HCl (pH 7.5) in a final volume of 4 ml. When done on liver tissue, 
the reaction mixture conta ined 3.0 to 11.7 mg wet liver weight that had 
been homogenized and then sonicated in 0.25 M sucrose-0.05 M Trls 
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HCl (pH 7.5), and the concentrations of ferrous sulfate and protopor-
p hyrin were increased to 125 UM . 
Nonenzymatic forma t ion of heme was measured with a t issue blank 
prepared by boiling a portion of the tissue sonicate fo r 10 min. T he 
level of nonenzymatic heme formation was sub tracted from the rate of 
heme formed by viable tissue to obtain the level of enzymatic heme 
formation. 
Measu.rem.ent of Protoporphyrinogen Oxidase Act ivity 
P rotoporphyrinogen oxidase activity was measured using a f1u oro-
metric assay [23,311. The reaction mix ture contained 0.5 to 2.0 mg of 
cell protein, I mM EDTA, 100 mM Tris HCl (pH 8.7) , 20 mg of Tween-
20, a nd 50 UM protoporphyrinogen in a fina l volume of 1.5 ml. Proto-
porphyrinogen was generated by red uction of protoporphyrin with 
sodium amalgam under nitrogen in the dark. A nonenzymatic control 
prepared by heating a portion of the ce ll sonicat.e at 75°C for 15 min , 
a reagent blank, and a protoporphyrin standard were run simul tane-
ously. The assay was started by addition of proLoporphyrinogen Lo the 
untreated tissue preparation and the nonenzymatic contro l. Each nask 
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FIG 1. Heme biosynthesis pathway. Enzymes which catalyze the 
steps in the pathway are as follows: (1) ALA synthase, (2) ALA 
dehydrase, (3) uroporphyrinogen I synthase, (4) uroporphyrinogen III 
cosyn thase, (5) uroporphyrinogen decarboxylase, (6) coproporphyri-
nogen oxidase, (7) protoporphyrinogen oxidase, (8) heme synthase, 
(ferrochelatase) . 
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was incubated at 37°C in the dark in room a ir. At 20-min in tervals for 
I hr of incubation, 0.1 ml of reaction mixture was removed and added 
to 2.9 ml of a solu tion that contained 5 mM glutathione, 1.0 mM EDTA, 
a nd 100 mM Tris HCl at a pH of 8. 7. The f1uorescence-emission intensity 
at 635 nm was measured with a Farrand spectrofluorom eter (4818 
photolilul t iplier tube) using an excitation wavelength of 405 nm. The 
concentrat ions of protoporphyrin in the sample solu tion and nonenzy-
matic control solu tion were determ ined by comparison to the proto-
porphyrin standard. T he diffe rence in protoporphyrin concentration 
between these solu tions represented protoporphyrin that had been 
genera ted enzymatica ll.v. 
RESULTS 
T h e fact t h at red cell a nd fecal protoporphyrin levels are 
increased in patients w it h protoporphyria points to a defect in 
h eme synth ase (ferroche latase) activity. Heme synth ase activ-
ity in li ver tissue obt.a ined from patients with protoporphyria 
was significantly redu ced compared to that in control liver 
tissue (Table III). The activ ity was reduced irrespective of t h e 
liver histology. N otably, h owever, t h e most severe reduction in 
activity (to 91 and 173 pmol heme/ mg protein/ hr) was found in 
t issue from t h e 2 patie n ts with severe ci.rrhosis and massive 
pigm e n t deposition . 
In o rder to provide add it io na l evid e nce that h eme synthase 
activ ity is defective in protoporphy ria , e nzym e activity in cul-
t ured skin fibr oblasts from patie nts was compared to that in 
celis from normal individuals. C ul tured fibroblasts are a n ideal 
t issue to examine s ince t h ey are a h omogeneous population of 
ceUs. Moreover, sin ce t h ey are cultured for several generations 
before assay, circulating fa ctors which might influ ence the 
e nzyme activ ity a r e eliminated. The results confinned that 
h eme synthase is defective in 'protoporphyria (Table IV). 
TABLE III . Liver heme synthase activity in patients with 
protoporphyria 
P rotoporphyria 
Control 
No. of i 
PULi en t.s 
7 
10 
pma! Heme/ mg prol e in/ hr 
559 ± 186 
2078 ± 298 
Mean ± SEM 
P < 0.01 
TABLE l. En zym.e defects in the porphyrias 
Disord er Enzyme rlefect Tissue where abnormality documented 
Acute in termi ttent prophyria 
Protoporphyria 
Hereditary coproporphyria 
Porphyria cutanea tru'da 
Familial 
Sporadic 
Variegate porphyria 
Congenital erythropoietic 
Unn amed 
Uroporphyrinogen I synthase 
Heme synthase 
Coproporphyrinogen oxidase 
Uroporphyrinogen decarboxylase 
U roporphyrinogen decarboxylase 
Heme synthase? 
Protoporphyrinogen 'oxidase ? 
Uroporphyrinogen III cosynthase/ 
Uroporphyrinogen I synthase imba l-
ance 
ALA dehydrase 
" References are indicated by the numbers in brackets. 
All tissues exam ined [1-6]" 
All tissues examined [7-12] 
All :tissues examined [13-15J 
All t issues examined [16,17] 
Liver only? [18-20] 
Bone marrow [21]; Fibroblasts [22] 
Fibroblasts [23] 
Red cells [24,25] 
Fibroblasts [26] 
Red cells [27,28] 
TABLE II . Manifesta.tions of protopolphyria a.nd variegate pOlphyria 
Inheritance 
Clincia l features 
Biochemical abnormali t ies 
Erythrocytes 
Feces 
Urine 
P rotoporphyrin 
Autosomal dominance 
Photosensitivity 
Hepatobiliru'y disease 
f P rotoporphyrin 
f Protoporphyrin 
None 
Variegate porphyria 
Autosomal dominance 
Skin fragili ty 
Neuropsychiatric symptoms 
None 
f Protoporphyrin, protoporphyrin-pep tides, and 
coproporphyrin 
i 8-Aminolevulinic acid, porphobilinogen, uropor-
phyrin, and coproporphyrin during acute attack 
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TABLE IV. Heme synlhase aClivily in cultUl·ed 8kin fibroblasls from 
members of 3 families with proloprophyria 
Children with protoprophyria 
Parents with enzyme defect 
Normal parents 
Normal controls 
No. pmo) Heme/ mg protein/ hr 
5 
3 
3 
8 
4.0 ± 0.8" 
5.8 ± 2.7" 
26.3 ± 1.9 
24 .9 ± 4.5 
Mean ± SEM 
" Signi ficant difference from control (P < 0.01) . 
TABLE V. Heme synlhase and proloporphyrinogen oxidase 
activities in cultured shin fibroblasts from patients with variegate 
porphyria 
No. Heme Protoporphyrinogen 
synthase oxidase 
pmo) heme/mg pmo) prolorol"phyrin/ mg 
prolein/ hl" prolein/ hr 
Variegate porphyria 5 36.4 ± 6.1 904 ± 132" 
Normal control 5 32.4 ± 5.9 2120 ± 250 
Mean ± SEM 
" Significant difference from control (P < 0.005). 
Since proto porphyria is inherited as an autosomal dominant 
disease, heme synthase activity should be defective in t he 
tissues of one of the parents of a patient with protoporphyria 
unless the disease represents a new mutation. Cul tured fibro-
blasts were available from 3 families in which protoporphyria 
was present. In each family, 2 or more children were affected 
with the disease. Heme synthase activity was diminished in 
cultured fibroblasts from one parent in each of the families, 
whereas that in cells from the other parent was normal (Table 
IV), consistent with a disease that has a dominant mode of 
inheritance. The enzyme defect was found in a parent from one 
family even though he had no biochemical or clinical manifes-
tations of protoporphyria. 
Although the biochemical abnormalities in variegate porphy-
ria are different from those in protoporphyria (Table II), the 
fact that fecal protoporphyrin is constantly elevated suggests 
there is also a defect in the terminal portion of the heme 
biosynthesis pathway in this disorder. Heme synthase and 
protoporphyrinogen oxidase activities were assayed in cultured 
skin fibroblasts from patients with variegate porphyria and 
compared to normal levels. Heme synthase activity was normal, 
whereas protoporphyrinogen oxidase was reduced to 43% of 
normal (Table V). 
DISCUSSION 
These studies illustrate how enzyme defects underlie the 
biochemical abnormalities which occur in the porphyrias. Heme 
synthase activity was shown to be deficient in liver tissue and 
cultured skin fibroblasts from patients with protoporphyria. 
Other investigators have demonstrated the enzyme defect in 
bone marrow cells and peripheral blood cells [8,9,11). As a 
resu lt of the enzyme defect, protoporphyrin accumulates in 
heme-forming cells, principally the developing red cell. As the 
red cell enters the circulation, the protoporphyrin diffuses out 
of the cell and binds to plasma proteins (Fig 2). It is subse-
quently taken up by the liver and excreted into bile, accounting 
for the high levels of fecal protoporphyrin which occur in 
patients with proto porphyria. 
The biochemical abnormalities observed in variegate porphy-
ria (Table II) are more difficult to explain on /the basis of the 
enzyme defect we have found. A defect in protoporphyrinogen 
oxidase should cause an accumulation of protoporphyrinogen, 
not of protoporphyrin. However, protoporphyrinogen rapidly 
and spontaneously oxidizes to protoporphyrin when exposed to 
air. Thus, protoporphyrinogen which is excreted in excess 
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FIG 2. Postulated basis for abnormal porphyrin metabolism in pro-
toporphyria. As a consequence of deficient heme synthase activity, 
protoporphyrin is accumulated in tissues and is excreted in excessive 
amounts in the feces. The red cell is the primary source of the elccess 
protoporphyrin, with a variable contribution from the hepatocyte. 
amounts by the liver would oxidize to protoporphyrin in bile or 
feces (Fig 3), accounting for the fact that fecal protoporphyrin 
is increased in patients with variegate porphyria. An addit ional 
factor must be present during acute attacks, since the itlter-
mediates of the heme .biosynthesis pathway which precede 
protoporphyrinogen are also excreted in excessive amounts. 
The activity of hepatic ALA syn thase, which is t he role-limiting 
enzyme in hepatic heme biosynthesis, is increased during acute 
attacks [1]. As a result, all the intermediates in t he pathway 
which precede the enzyme block may be formed and excreted 
in increased amounts (Fig 3). 
In contrast to our finding that heme synthase activity is 
normal in cul tUJ"ed fibroblasts from patients with variegate 
porphyria, Becker and co-workers found approximately 50~ 
reduction in heme synthase activity in cultured fibroblasts and 
bone marrow cells from patients with the disorder [21,22]' They 
have postulated that an abnormality in heme synthase activity 
may be common to protoporphyria and variegate porphYria. 
There is no ready explanation for the discrepancy between their 
studies and ours. Although this may be due to differences in 
methodology, it is conceivable that some patients have a defect 
only in protoporphyrinogen oxidase, as we observed, whereas 
others have a defect in both protoporphyrinogen oxidase and 
heme synthase. Further studies in more pedigrees with the 
disease are req uired to answer this question. 
T he nature of the enzyme defect has not been well-charac-
terized in any of the porphyrias. Recently, uroporphyrin~gen 
synthase has been pur ified by Anderson and Desnick [32], and 
the enzyme a bnormality in acute intermittent porphyri lJ h as 
been investigated. Preliminary data indicate that the ent.:Yme 
deficiency in most patients results from a structural gene defect 
[33]. It will be of interest to learn if more than one defect in 
w·oporphyrinogen synthase can cause acute intermittent por-
phyria (in other words, is there genetic heterogeneity ill t he 
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PORPHYRIN MET ABOL/8M IN VARIEGATE PORPHYRIA 
Remission 
ALA 
SY NTHA SE glycine 
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PROTO~~::;:'~VERINOGE N + 
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Relapse 
bil e --- no nenz y m a t ic oxidation 
t o protoporphyrin 
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FIG 3, Postulated basis for abnormal porphyrin metabolism in va riegate porphyria. As a consequence of deficient protoporphyrinogen oxidase 
activi ty, protoporphyrinogen is excessive amounts in bi le. Nonenzymatic oxidation of protoporphyrinogen to protoporphyrin subsequently occurs, 
explaining why fecal protoporphyrin is constantly elevated in this disorder. During acute attacks, hepatic ALA synthase markedly increases, and 
t he intermediates of the pathway which precede protoporphyrinogen are also excreted in increased amounts. 
disorder) . This is likely to be the case in several of the porphy-
rias. 
Enzyme activity is defective in the tissues of some individuals 
w ho do not have biochemical manifestations of porphyria, as 
illustrated by other studies in parents of children affected with 
protoporphyria (Table IV) and by studies of other investigators 
[2,17]. Moreover, biochemical manifestations in individual pa-
tients vary from one period to another. Thus, other factors are 
important in causing biochemical expression of the disease. The 
req uirement for hepatic heme biosynthesis is one such factor . 
A greater dema nd for heme biosynthesis may necessitate a n 
increase in ALA synthase activity. This will increase the for-
mation of the intermediates which precede the enzyme defect 
a nd enhance the biochemical abnormalities. ALA synthase 
activity is increased markedly in the livers of pat ients with 
variegate porphyria, acute intermittent porphyria, and heredi-
tary coproporphyria during acute attacks [1,34- 37]. When the 
patien ts are in remission, hepatic ALA synthase activity is 
lower, a nd the excretion of porphyrins and porphyrin precursors 
is less [1,37]. 
Other factors may modify the enzyme defects. For example, 
the level of iron influences the degree to which protoporphyrin 
accumulates in fibroblasts cultured from patients with proto-
porphyria (38). Ferrous iron also a ppear s to inhibit uropor-
p h yrinogen decal'boxylase activity in crude liver extracts [39). 
S ince patients with porphyria cuta nea ta rda cha racteristically 
h a ve hepatic hemosiderosis, t his may bring out the disease in 
patients who already have reduced enzym e activity. Further 
identification of factors which modify the enzyme defects will 
increase our understanding of the fluctuations which occur in 
the biochemical manifestations of the prophyrias. 
The defect in heme synthase activi ty has been found in all 
tissues from patients wi t h protoporphyria. S imilarly, t he en-
zym e defects in acute intermittent porphyria, hereditary co pro-
porphyria, a nd familial porphyria cuta nea tarda have been 
fo und in all tissues examined. This refl ects the genetic nature 
of these disorders. However, it raises the question why the red 
cell appears to be the principal site of expression of the bio-
chemical a bnormality in protoporphyria, whereas the live r is 
the m ajor s ite in most of the other porphy rias [40]. One possi-
bility is that enzyme defects in nonhepatic t issues do not reduce 
the activities of most of the enzym es to critical levels such that 
porphy rins a nd porphyrin precm sors accumulate . In cultmed 
skin fibroblasts, for example, protoporphyrinogen oxidase activ-
ity is high compared to t hat of ALA synthase, W'oporphYl'inogen 
I synthase, a nd heme synthase (Fig 4). Thus, a defect in 
HEME PATHWAY ENZYMES IN CULTURED FIBROBLASTS 
pmol porphyrin equivalents/mg protein/hr at 37°c 
g lyCine J Q. " !I !l 4 38 I 1 9 
succmyl - CoA ALA POrpho bilinoge n ___ uf o p orphyrin ogon 
ALA "LA uno I Uq O III 
S VNltiA SE O[IWOR"S£ SV N THASE COS ... N1HA SE 
coporphyrlnogo n 
URO COPRQ 
DECAROOleV LA S[ OX IDA SE 
tlI!M[ 
SVNltlA SE 
p l o l OpOlphyrinogcn p r o toporph yrin 
J'l10 1 0 
OX IDA SE 
heme 
FIG 4. Specific activities of heme pathway enzymes in cult.ured skin 
fibrob lasts. Relative activities of the enzymes are shown in terms of 
porphyrin equiva lents generated. When more than one value is given, 
the data were generated in di fferent laboratories (see references in 
Table [l. 
protoporphYl'inogen ox idase does not cause porphyrin meta b-
olism to be al tered in these cells, whereas a defect in heme 
syn thase will [23,38]. 
The past decade has brought progress in our understanding 
of the pathogenes is of t he biochemical abnormal ities in the 
porphyrias. Several inte resting a nd important questions have 
a risen as a resul t of this information a nd require further inves-
t igation. 
Drs. Herbert Bonkowsky, David Brenner, and Maurice J. Mahoney 
had indi pensa ble roles in the performance of these studies. Juan 
Zaccru'ia, Rosa lie Blunden, Andi Bru'lczak, Janice Munroe, and Rose 
Allen provided technical assistance. 
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